Receptor-binding profiles of antipsychotics: Clinical strategies when switching between agents

Peter F. Buckley

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

In spite of apparent improvements in the pharmacotherapy of schizophrenia, many patients still demonstrate an incomplete therapeutic response to antipsychotic medication and/or intolerable adverse effects, necessitating a change in their medication regimen. The switch from one antipsychotic to another, however, is not without challenges and can be complicated by withdrawal-emergent adverse effects that prompt the patient or the clinician to abort the switch. The extent to which these adverse events can be predicted by comparing the effects of the old and new antipsychotic medications on various receptor systems, including dopaminergic, muscarinic, and histaminergic receptors, is of considerable clinical and research interest. For example, patients receiving a sedating antipsychotic with high affinity for histamine H, receptors could experience rebound insomnia if switched to a less sedating agent with a low affinity for H1 receptors. An understanding of the differential receptor-binding profiles of the various antipsychotics can help clinicians anticipate and manage potential clinical issues that may be encountered when switching antipsychotic therapy.

Original languageEnglish (US)
Pages (from-to)5-9
Number of pages5
JournalJournal of Clinical Psychiatry
Volume68
Issue numberSUPPL. 6
StatePublished - Jul 10 2007

Fingerprint

Antipsychotic Agents
Histamine Receptors
Histamine H1 Receptors
Sleep Initiation and Maintenance Disorders
Muscarinic Receptors
Schizophrenia
Drug Therapy
Therapeutics
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Receptor-binding profiles of antipsychotics : Clinical strategies when switching between agents. / Buckley, Peter F.

In: Journal of Clinical Psychiatry, Vol. 68, No. SUPPL. 6, 10.07.2007, p. 5-9.

Research output: Contribution to journalReview article

@article{aad5d9f636d0426ca70fffa8c46794d2,
title = "Receptor-binding profiles of antipsychotics: Clinical strategies when switching between agents",
abstract = "In spite of apparent improvements in the pharmacotherapy of schizophrenia, many patients still demonstrate an incomplete therapeutic response to antipsychotic medication and/or intolerable adverse effects, necessitating a change in their medication regimen. The switch from one antipsychotic to another, however, is not without challenges and can be complicated by withdrawal-emergent adverse effects that prompt the patient or the clinician to abort the switch. The extent to which these adverse events can be predicted by comparing the effects of the old and new antipsychotic medications on various receptor systems, including dopaminergic, muscarinic, and histaminergic receptors, is of considerable clinical and research interest. For example, patients receiving a sedating antipsychotic with high affinity for histamine H, receptors could experience rebound insomnia if switched to a less sedating agent with a low affinity for H1 receptors. An understanding of the differential receptor-binding profiles of the various antipsychotics can help clinicians anticipate and manage potential clinical issues that may be encountered when switching antipsychotic therapy.",
author = "Buckley, {Peter F.}",
year = "2007",
month = "7",
day = "10",
language = "English (US)",
volume = "68",
pages = "5--9",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Receptor-binding profiles of antipsychotics

T2 - Clinical strategies when switching between agents

AU - Buckley, Peter F.

PY - 2007/7/10

Y1 - 2007/7/10

N2 - In spite of apparent improvements in the pharmacotherapy of schizophrenia, many patients still demonstrate an incomplete therapeutic response to antipsychotic medication and/or intolerable adverse effects, necessitating a change in their medication regimen. The switch from one antipsychotic to another, however, is not without challenges and can be complicated by withdrawal-emergent adverse effects that prompt the patient or the clinician to abort the switch. The extent to which these adverse events can be predicted by comparing the effects of the old and new antipsychotic medications on various receptor systems, including dopaminergic, muscarinic, and histaminergic receptors, is of considerable clinical and research interest. For example, patients receiving a sedating antipsychotic with high affinity for histamine H, receptors could experience rebound insomnia if switched to a less sedating agent with a low affinity for H1 receptors. An understanding of the differential receptor-binding profiles of the various antipsychotics can help clinicians anticipate and manage potential clinical issues that may be encountered when switching antipsychotic therapy.

AB - In spite of apparent improvements in the pharmacotherapy of schizophrenia, many patients still demonstrate an incomplete therapeutic response to antipsychotic medication and/or intolerable adverse effects, necessitating a change in their medication regimen. The switch from one antipsychotic to another, however, is not without challenges and can be complicated by withdrawal-emergent adverse effects that prompt the patient or the clinician to abort the switch. The extent to which these adverse events can be predicted by comparing the effects of the old and new antipsychotic medications on various receptor systems, including dopaminergic, muscarinic, and histaminergic receptors, is of considerable clinical and research interest. For example, patients receiving a sedating antipsychotic with high affinity for histamine H, receptors could experience rebound insomnia if switched to a less sedating agent with a low affinity for H1 receptors. An understanding of the differential receptor-binding profiles of the various antipsychotics can help clinicians anticipate and manage potential clinical issues that may be encountered when switching antipsychotic therapy.

UR - http://www.scopus.com/inward/record.url?scp=34347405501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347405501&partnerID=8YFLogxK

M3 - Review article

C2 - 17650053

AN - SCOPUS:34347405501

VL - 68

SP - 5

EP - 9

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 6

ER -